Shares of Omnicell, Inc. (NASDAQ:OMCL – Get Free Report) have earned an average recommendation of “Hold” from the seven research firms that are covering the company, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $37.83.
A number of analysts recently issued reports on the stock. Benchmark reissued a “buy” rating and set a $38.00 price target on shares of Omnicell in a report on Monday, July 15th. Wells Fargo & Company increased their target price on shares of Omnicell from $26.00 to $30.00 and gave the stock an “equal weight” rating in a research note on Friday, August 2nd. Bank of America lifted their price target on Omnicell from $34.00 to $44.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Barclays raised Omnicell from an “underweight” rating to an “equal weight” rating and raised their price objective for the company from $26.00 to $39.00 in a report on Friday, August 2nd. Finally, StockNews.com downgraded Omnicell from a “buy” rating to a “hold” rating in a research note on Thursday, September 19th.
Read Our Latest Analysis on OMCL
Omnicell Trading Down 0.5 %
Omnicell (NASDAQ:OMCL – Get Free Report) last posted its earnings results on Thursday, August 1st. The company reported $0.51 EPS for the quarter, topping the consensus estimate of $0.14 by $0.37. Omnicell had a positive return on equity of 2.52% and a negative net margin of 1.92%. The firm had revenue of $276.80 million for the quarter, compared to analyst estimates of $254.41 million. During the same period last year, the company earned $0.29 earnings per share. Omnicell’s revenue for the quarter was down 7.4% compared to the same quarter last year. Research analysts forecast that Omnicell will post 0.64 earnings per share for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in OMCL. Panagora Asset Management Inc. purchased a new stake in shares of Omnicell during the fourth quarter worth $1,319,000. Vanguard Group Inc. grew its stake in Omnicell by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 5,651,732 shares of the company’s stock valued at $165,200,000 after acquiring an additional 80,312 shares in the last quarter. Mutual of America Capital Management LLC raised its holdings in Omnicell by 197.9% in the 1st quarter. Mutual of America Capital Management LLC now owns 124,600 shares of the company’s stock valued at $3,642,000 after acquiring an additional 82,774 shares during the last quarter. Assenagon Asset Management S.A. lifted its stake in Omnicell by 61.3% in the 2nd quarter. Assenagon Asset Management S.A. now owns 599,928 shares of the company’s stock worth $16,240,000 after purchasing an additional 228,093 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new position in shares of Omnicell during the 1st quarter worth approximately $684,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.
About Omnicell
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.
Further Reading
- Five stocks we like better than Omnicell
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Rocket Lab Stock Soars: Should Investors Chase the Rally?
- Conference Calls and Individual Investors
- KB Home Slips After Earnings: What’s Next for Homebuilders?
- ETF Screener: Uses and Step-by-Step Guide
- Micron Stock Soars as AI Demand Fuels Big Q4 Earnings Beat
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.